Advertisement


Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study

2024 ASCO Annual Meeting

Advertisement

Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Today I am going to talk about IMC-F106C, which is an ImmTAC now called brenetafusp and this is made by Immunocore. We're all familiar with ImmTACs, immune-mobilizing T-cell receptors against cancer. It's a bispecific that targets CD3 on one side and a tumor produced protein on the other. This one targets PRAME, proteins of PRAME. This is an update of the data that I presented at ESMO 2022 about this ImmTAC that targets PRAME. In 2022 we talked about all solid tumors. This update is in cutaneous melanoma. 47 patients with single agent brenetafusp and then a nine patient combination with pembrolizumab looking at safety and efficacy. We know that ImmTACs work. This was proven with tebentafusp in uveal melanoma. We know that ImmTACs can be combined with anti-PD-1, PD-L1 and anti-CTLA-4. We did that in cutaneous melanoma and published it in JTSI. This shows a updated expansion in escalation cohorts in cutaneous melanoma. And what we saw was very interesting. We saw response, of course. There is a clinical benefit of about 50%. There is a response rate of 11% and then stable disease or better, a little shrinkage from stable diseases there. What we found is this drug, the clear benefit comes in stable disease or better. It's not just an overall response with this mechanism. We also found that the responses were durable. In those patients that had stable disease, minimal reduction or better, they had a long-term durable benefit. We saw this benefit in patients who were PRAME positive, which gives credence to the mechanism that this ImmTAC is targeting PRAME. We saw it in BRAF mutant patients. We saw it in heavy tumor burden patients and we saw it in patients with melanoma that have brain and liver metastases or both. And this is what we're looking for. This cohort of patients were heavily pretreated. They had had at least two PD-1 containing regimens. 80% had seen anti-CTLA-4 and four fifths of those had seen anti-CTLA-4 and PD-1 together. And about 38% had seen another immuno-oncology compound on top of that, which is why this is so interesting. Toxicity was tolerable, mainly grade one two cytokine release syndrome. And what we saw was it was tolerable when combined anti-PD-1 therapy. There were nine patients, six of them were primary resistant. And what we saw there is molecular response and a 1PR. And that was held throughout in the combination cohorts of brenetafusp and anti PD-1 with pembrolizumab in other solid tumors. Other solid tumors we saw that tolerability. Why is this important? Well, this is another tool in our toolkit against melanoma. Why else is it important? Melanoma sets the standard for other solid tumors. We've seen responses in other solid tumors as I presented endometrial, ovarian, uveal. And we're looking at it in lung cancer and that's interesting. What we also found is that there is a T-cell signature that indicates better response. Naive and STEM central memory T-cells, when those were higher, those patients were the ones that benefited the most. And that was found in earlier lines of therapy. We are now accruing to a major phase three trial of brenetafusp and nivolumab versus nivolumab alone or nivolumab and ipilimumab in the first line. And this will show the benefit of this drug in cutaneous melanoma. I look forward to accruing to that study. I look forward to understanding the mechanism of action of this class of drugs. I have no doubt that when we present more data on the T-cell fitness signature and in other cohorts upcoming meetings, that you'll be as excited about this platform and about this drug, brenetafusp, as I am.

Related Videos

Breast Cancer

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).

Clifford A. Hudis, MD: A Message From ASCO’s CEO

Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Breast Cancer

Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).

Bladder Cancer

Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Urothelial Carcinoma: Expert Commentary on Two Key Abstracts

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).

Advertisement

Advertisement




Advertisement